Cigna Corp.
https://www.cigna.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cigna Corp.
US Adalimumab Outlook Brightens At Mid-Point Of 2024
The latest figures on uptake of rivals to AbbVie's Humira in the US show adalimumab biosimilars beginning to capture significant market share from the originator after an initially slow start in 2023.
Humira Market Erosion Is Continuing As Expected, AbbVie Says
With adalimumab biosimilar market share increasing in the US, AbbVie says revenue erosion is on its expected pace, driven mainly by discounts. Skyrizi, Rinvoq continue growth trajectories.
Canary Speech’s Voice AI Can Help Detect Alzheimer’s With 40-Second Conversation
AI voice tech start-up Canary Speech is developing algorithmic models for detecting behavioral health, progressive neurological and cognitive diseases based on a 40-second recording of speech. Medtech Insight caught up with Canary CEO Henry O’Connell at DHIS West to learn more about the company and its plans.
Blue Shield Of California’s Pharmacy Benefit Overhaul Could Still See Boost From Transparency Legislation
The payor’s multiyear plan to ditch the traditional PBM model and use multiple vendors has drawn a lot of skepticism from other actors in the health care system, but Blue Shield is hoping that it can help give policymakers some momentum, VP Lum tells the Pink Sheet.
Company Information
- Industry
- Pharmaceuticals
- Services
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice